Komori
Results4483JMDC Inc.Information and Communications, Services and Others

Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [IFRS]

For the interim period of the fiscal year ending March 2027, revenue increased 19.5% year on year and operating profit increased 14.4%. The full-year earnings forecast was left unchanged, but no annual dividend forecast was provided for the current fiscal year.

Worth reading
29Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
4490
¥ million
Wording
Conditional
How definitive the wording is.

Results for this period

Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRS
Net Sales27,571¥ millionYear on year +19.5%Progress 45.6%
Operating profit4,604¥ millionYear on year +14.4%Progress 40.0%
Ordinary income4,340¥ millionYear on year +18.7%
Net income attributable to owners of the parent2,951¥ millionYear on year +24.2%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥45.10
Financial position at period-end
Total assets158,611¥ million
of which net assets 84,957 ¥ millionEquity ratio 53.5%vs. prior year-end +0.7pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Cash inflows and outflows
Operating+8,294
Investment-3,250
Financials-4,890
Net change+154

Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.

Cash and cash equivalents at end of period¥29,104 million
Segment revenueHealth Big Data ¥24,152 million (YoY +21.4%), Telemedicine ¥3,419 million (YoY +7.3%)
Segment profitHealth Big Data ¥5,511 million (YoY +14.8%), Telemedicine ¥1,370 million (YoY +19.0%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥60,500 million (YoY +19.9%)
Operating profit¥11,500 million (YoY +9.3%)
Pretax profit¥11,000 million (YoY +10.4%)
Profit for the period¥7,200 million (YoY +5.7%)
Profit for the period attributable to owners of the parent¥7,100 million (YoY +4.9%)
Annual Dividend Forecast¥18 → Not disclosed
Factors Behind Changes in Business Performance

The number of health insurance societies and other organisations, transaction value with pharmaceutical companies and insurers, the number of IDs issued for Pep Up, and the number of medical institutions using the remote image-reading service all increased or expanded.

Disclosure regarding the going concern assumption

No applicable matters. The notes on the going concern assumption state that there are no applicable matters.

Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 Not disclosed
Material subsequent eventsThere are no applicable matters.
Depreciation and amortization¥1,762 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End65,448,208 shares
Treasury Shares at Period-End816 shares
Results for this period
ItemDetails
Fiscal Period ClassificationInterim period (second quarter)
Accounting standardsIFRS
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 September 2026
Net Sales¥27,571 million (YoY +19.5%)
Operating profit¥4,604 million (YoY +14.4%)
Ordinary income¥4,340 million (YoY +18.7%)
Profit attributable to owners of the parent¥2,951 million (YoY +24.2%)
Net income per share¥45.10
Equity ratioEnd of the current fiscal period 53.5% / End of previous period 52.8%
Total assets¥158,611 million
Net assets¥84,957 million
Cash flows from operating activities¥8,294 million
Cash flows from investing activities¥-3,250 million
Cash flows from financing activities¥-4,890 million
Cash and cash equivalents at end of period¥29,104 million
Full-year earnings forecastNet Sales ¥60,500 million (YoY +19.9%) / Operating profit ¥11,500 million (YoY +9.3%) / Pretax profit ¥11,000 million (YoY +10.4%) / Profit for the period ¥7,200 million (YoY +5.7%) / Profit for the period attributable to owners of the parent ¥7,100 million (YoY +4.9%)
Annual Dividend Forecast¥18 → Not disclosed
Segment revenueHealth Big Data ¥24,152 million (YoY +21.4%), Telemedicine ¥3,419 million (YoY +7.3%)
Segment profitHealth Big Data ¥5,511 million (YoY +14.8%), Telemedicine ¥1,370 million (YoY +19.0%)
Depreciation and amortization¥1,762 million
Disclosure regarding the going concern assumptionNo applicable matters. The notes on the going concern assumption state that there are no applicable matters.
Change in accounting policyChanges due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement Not disclosed
Material subsequent eventsThere are no applicable matters.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End65,448,208 shares
Treasury Shares at Period-End816 shares
Factors Behind Changes in Business PerformanceThe number of health insurance societies and other organisations, transaction value with pharmaceutical companies and insurers, the number of IDs issued for Pep Up, and the number of medical institutions using the remote image-reading service all increased or expanded.
Items this document does not state (9)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The number of clients such as health insurance societies, transaction value with pharmaceutical companies and insurers, the number of IDs issued for Pep Up, and the number of medical institutions using the remote image-reading service all increased or expanded.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending March 2027 [IFRS] | JMDC Inc. (4483) timely disclosure | Komori